Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30879451 | 0.92 | GLS (0.45) | DCTPP1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL24997051 | 0.83 | HTR2A (0.46) | DCTPP1BRD4MEN1KMT2ANPBWR1 | |
| SCHEMBL31357438 | 0.83 | HTR2A (0.46) | DCTPP1BRD4MEN1KMT2ANPBWR1 | |
| SCHEMBL20401101 | 0.81 | GLS (0.57) | DCTPP1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL28899217 | 0.77 | MAPT (0.52) | MAPTSMN1; SMN2MEN1KMT2ANPBWR1 | |
| SCHEMBL4231911 | 0.76 | ALDH1A1 (0.54) | MAPTMEN1KMT2ACRHBPCRHR2 | |
| SCHEMBL24996626 | 0.75 | QPCT (0.46) | DCTPP1BRD4MEN1KMT2ANPBWR1 | |
| SCHEMBL30879444 | 0.75 | QPCT (0.46) | DCTPP1BRD4MEN1KMT2ANPBWR1 | |
| SCHEMBL27741405 | 0.74 | MAPT (0.46) | DCTPP1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL9478940 | 0.74 | NPC1 (0.50) | DCTPP1MAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391931-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-28 | — | — | US | disclosed |
| CN-117980309-A | Tricyclic fused pyrimidine compounds useful as HER2 inhibitors | 百时美施贵宝公司 | 2024-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391931-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | ERBB2, ERBB3, EGFR | DCTPP1 328/4885BRD4 495/4885MAPT 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.